Metsera, Inc. (MTSR)
NASDAQ: MTSR · Real-Time Price · USD
51.70
-0.42 (-0.81%)
At close: Oct 2, 2025, 4:00 PM EDT
51.53
-0.17 (-0.33%)
After-hours: Oct 2, 2025, 7:45 PM EDT
Metsera Employees
As of December 31, 2024, Metsera had 81 total employees, including 74 full-time and 7 part-time employees.
Employees
81
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$3,800,272
Market Cap
5.44B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 81 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
MTSR News
- 2 days ago - Healthy Returns: Pfizer's new obesity bet, Metsera, releases encouraging data on lead drug - CNBC
- 2 days ago - Metsera Posts Promising Weight-Loss Drug Results. It Could Be a Win for Pfizer. - Barrons
- 3 days ago - Metsera's obesity drug shows promising weight loss in mid-stage trials - Reuters
- 3 days ago - Metsera Reports Positive Phase 2b Results for First- and Best-in-Class Ultra-long Acting GLP-1 RA Candidate MET-097i, Enabling Rapid Transition into Phase 3 - GlobeNewsWire
- 9 days ago - METSERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Metsera, Inc. - MTSR - Business Wire
- 10 days ago - Pfizer bets $7.3 billion on obesity drugs with Metsera buy - Fast Company
- 10 days ago - Pfizer Jumps Into Weight-Loss Drug Segment With $7.3 Billion Metsera Deal - Investopedia
- 10 days ago - Pfizer Tries To Revitalize Obesity Portfolio With $5 Billion Matsera Deal - Benzinga